Welcome to our dedicated page for Adial Pharmaceuticals SEC filings (Ticker: ADIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Adial is a clinical-stage biopharmaceutical company focused on therapies for addictions and related disorders, and its filings document both the scientific and financial aspects of this development-stage business.
Investors can review Current Reports on Form 8-K that describe material events such as End of Phase 2 (EOP2) meeting outcomes with the U.S. Food and Drug Administration (FDA), Nasdaq listing compliance notices, equity offerings, at-the-market sales agreements, warrant amendments, and stockholder approvals for changes to the Certificate of Incorporation and equity incentive plans. These filings provide detail on the regulatory feedback shaping the AD04 Phase 3 adaptive trial design, including biomarker-positive and biomarker-negative cohorts, primary efficacy endpoints based on heavy drinking days, and statistical planning.
Filings also outline capital structure and financing arrangements, including best efforts public offerings of common stock and warrants, pre-funded warrants, and at-the-market programs. Disclosures explain how proceeds are intended for working capital and general corporate purposes and describe conditions such as exercise prices, expiration dates, and stockholder approval requirements for warrant exercises.
Through Stock Titan, users can track Nasdaq listing and compliance disclosures, including letters regarding stockholders’ equity thresholds, minimum bid price requirements, and extensions granted to regain compliance. These documents help clarify the ongoing eligibility of ADIL shares for trading on the Nasdaq Capital Market.
In addition to raw documents, Stock Titan offers AI-powered summaries that highlight key points from Adial’s 8-Ks and other filings, helping readers quickly understand complex topics such as clinical trial design guidance, intellectual property steps around AD04, and changes to authorized share counts or incentive plans. This page is a resource for anyone analyzing how Adial’s regulatory, clinical, and financing activities are reflected in its official SEC record.
Adial Pharmaceuticals has scheduled its 2025 Annual Meeting for August 1, 2025, with several significant proposals up for stockholder vote. Key proposals include:
- Election of two Class I directors for three-year terms
- Approval to issue up to 6.7 million shares for May 2025 warrant exercises and 19.4 million shares for June 2025 warrant exercises
- Implementation of a reverse stock split at a ratio between 1-for-2 and 1-for-25
- Increase in authorized common stock from 50 million to 100 million shares
- Expansion of 2017 Equity Incentive Plan share pool from 2 million to 5 million shares
The meeting will be held at Charlottesville, Virginia. CBIZ CPAs P.C. to be ratified as independent auditor. The record date is June 4, 2025. The proposals reflect significant corporate restructuring efforts, including potential share dilution and capital structure changes that could materially impact stockholders.
Adial Pharmaceuticals, Inc. (ADIL) – Schedule 13G filing (Event date: 17 Jun 2025)
The filing discloses the equity position of three related reporting persons—Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC—following a Securities Purchase Agreement (SPA) dated 17 Jun 2025. As of the close of business on 20 Jun 2025 they jointly held 446,282 common shares, equal to 2.8 % of ADIL’s outstanding stock (10,434,695 shares reported outstanding on 11 Jun 2025). Voting and dispositive power over these shares is shared.
The SPA provides for the issuance of up to 1,150,000 additional common shares and three tranches of warrants (collectively up to 3,091,225 shares) to Intracoastal. Each warrant contains ownership “blocker” clauses (4.99 %–9.99 %) that limit exercisability. Without the blockers—and assuming all warrants were exercisable—the reporting persons’ potential beneficial ownership could rise to 4,229,225 shares.
At present, because the blocker provisions are in force and warrant tranches 2 & 3 require shareholder approval before becoming exercisable, the group remains below the 5 % Schedule 13D threshold and files on a passive 13G basis.
Key take-aways for investors
- Current stake: 2.8 % (non-controlling, passive).
- Immediate dilution risk: 1.15 M new shares to be issued at SPA closing.
- Additional dilution risk: up to 3.09 M warrant shares dependent on blocker limits and shareholder approval.
- Ownership reduction from the initial 9.99 % cap to 2.8 % suggests limited near-term influence by the reporting group.
Adial Pharmaceuticals, Inc. (ADIL) reported the completion of a best-efforts public offering on 18 June 2025 that generated gross proceeds of approximately $3.6 million. The transaction combined newly issued common shares, pre-funded warrants and two new warrant series, materially increasing the company’s potential fully-diluted share count.
Key terms of the offering
- 5,341,200 new common shares and 5,758,800 pre-funded warrants were sold. Each share or pre-funded warrant unit was paired with one Series D and one Series E warrant.
- Pricing: $0.3251 per common share unit; $0.3241 per pre-funded unit.
- Aggregate securities created: up to 11,100,000 Series D warrant shares (exercise price $0.35; 5-year life) and 8,325,000 Series E warrant shares (exercise price $0.35; 18-month life).
- Pre-funded warrants have a de minimis $0.001 exercise price and no expiration; all warrants include customary anti-dilution and cashless-exercise features and a 4.99%/9.99% ownership cap.
- The securities were registered on Form S-1 (File No. 333-287826) declared effective 16 June 2025.
Use of proceeds: The company intends to deploy the net funds for working capital and general corporate purposes.
Placement & lock-ups: A.G.P./Alliance Global Partners acted as exclusive placement agent, earning 7.0 % of gross proceeds (less a 3.5 % credit on tail-list investors) plus a 1.0 % management fee and up to $75,000 in expense reimbursement. The purchase and placement agreements restrict additional equity issuances for 30 days (general) and 60 days (ATM/variable rate), with limited exceptions.
Warrant amendments: Concurrently, the exercise price on existing Series B-1 (2,482,270 shares) and Series C-1 (4,025,000 shares) warrants was reduced to $0.35. Expirations were extended to 17 Jun 2030 (B-1) and 17 Dec 2026 (C-1), subject to future shareholder approval obligations.
Investor impact
- The raise strengthens near-term liquidity but is modest relative to the potential issuance of up to 30 million additional shares, implying significant dilution.
- Common warrant exercise is conditional on shareholder approval to be secured within 120 days; failure to obtain approval could delay additional dilution or cash inflow.
- The repricing and term extension of prior warrants increases the likelihood of further share issuance at $0.35.
Overall, the 8-K details substantial low-priced equity and warrant issuance that improves cash resources but materially increases future dilution risk.